https://aulosbio.com/ 2022-01-07T12:54:58+00:00 1.00 https://aulosbio.com/about-us/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/about-us/board-of-directors/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/about-us/corporate-presentation/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/about-us/investors/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/about-us/leadership/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/about-us/mission-and-values/ 2025-01-07T12:54:58+00:00 0.80 https://aulosbio.com/ca-compliance/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/terms-of-use/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/careers/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/about-us/investor-relations/ 2025-01-07T12:54:58+00:00 0.80 https://aulosbio.com/contact/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/newsroom/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/newsroom/media-inquiries/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/newsroom/in-the-news/ 2025-01-07T12:54:58+00:00 0.80 https://aulosbio.com/about-us/mission-and-values/ 2025-01-07T12:54:58+00:00 0.80 https://aulosbio.com/our-approach/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/our-approach/abstracts-and-publications/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/our-approach/platform/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/our-pipeline/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/privacy-policy/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/social-media/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/new-phase-2-data-for-aulos-biosciences-imneskibart-reveal-clinical-activity-in-melanoma-and-non-small-cell-lung-cancer/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-to-present-updated-phase-2-data-for-imneskibart-au-007-in-melanoma-and-non-small-cell-lung-cancer-at-40th-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-presents-new-phase-2-data-for-au-007-demonstrating-continued-strong-anti-tumor-activity-in-advanced-cancers-at-aacr-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-doses-first-patient-in-phase-2-cohort-evaluating-au-007-in-combination-with-nivolumab-for-second-line-treatment-of-melanoma/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-au-007-in-melanoma-at-aacr-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-doses-first-patient-in-phase-2-cohort-evaluating-the-combination-of-avelumab-and-au-007-for-the-treatment-of-non-small-cell-lung-cancer/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/strong-evidence-of-au-007s-anti-tumor-activity-in-advanced-solid-tumor-cancers-presented-at-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-presents-phase-2-dose-selection-data-for-novel-il-2-therapeutic-antibody-au-007-at-36th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-announces-presentation-detailing-phase-2-dose-selection-for-au-007-in-solid-tumor-treatment-at-36th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-antibody-au-007-at-39th-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-provides-positive-interim-phase-1-2-data-from-au-007-at-2024-asco-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-enters-into-clinical-trial-collaboration-and-supply-agreement-with-merck-kgaa-darmstadt-germany-to-study-combination-of-bavencio-with-au-007/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-to-present-updated-phase-1-2-clinical-trial-results-for-novel-il-2-therapeutic-au-007-in-advanced-solid-tumor-cancers-at-2024-asco-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/first-patient-dosed-in-phase-2-portion-of-aulos-biosciences-phase-1-2-clinical-trial-for-au-007-a-computationally-designed-il-2-antibody-for-solid-tumor-cancers/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-advances-au-007-to-phase-2-portion-of-phase-1-2-study-evaluating-computationally-designed-il-2-antibody-for-treatment-of-solid-tumors/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/new-phase-1-dose-escalation-data-show-well-tolerated-safety-profile-and-anti-tumor-activity-for-aulos-biosciences-au-007-at-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-new-au-007-phase1-dose-escalation-data/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-to-present-encouraging-pharmacodynamic-data-for-au-007-from-phase-1-dose-escalation-cohorts-at-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutic/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-announces-presentation-of-updated-safety-and-efficacy-data-from-first-in-human-phase-1-2-clinical-trial-of-au-007-at-38th-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-raises-20-million-in-series-a-extension-financing-from-apple-tree-partners/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/interim-results-from-phase-1-2-clinical-trial-in-solid-tumor-cancers-demonstrate-aulos-biosciences-au-007-is-well-tolerated-and-uniquely-reduces-regulatory-t-cells/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/first-u-s-patient-dosed-in-aulos-biosciences-phase-1-2-clinical-trial-of-au-007-a-novel-il-2-therapeutic-for-the-treatment-of-solid-tumors/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-presents-initial-data-from-first-in-human-phase-1-2-clinical-trial-of-computationally-designed-antibody-au-007-at-37th-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-announces-fda-clearance-of-ind-application-for-au-007-a-novel-immunotherapy-for-the-treatment-of-solid-tumors/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-to-present-initial-safety-data-from-first-in-human-phase-1-2-clinical-trial-of-il-2-therapeutic-au-007-at-37th-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-presents-poster-on-phase-1-2-clinical-trial-of-computationally-designed-il-2-antibody-au-007-at-2022-asco-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-initiates-phase-1-2-clinical-trial-of-il-2-therapeutic-au-007-for-the-treatment-of-solid-tumors/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-announces-presentation-on-first-in-human-phase-1-2-clinical-trial-of-novel-il-2-therapeutic-au-007-at-2022-asco-annual-meeting/ 2025-08-10T15:34:55+00:00 0.80 https://aulosbio.com/aulos-bioscience-announces-preclinical-data-demonstrating-ability-of-novel-il-2-therapeutic-au-007-to-eliminate-solid-tumors/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/aulos-bioscience-receives-hrec-approval-to-initiate-first-in-human-clinical-trial-evaluating-anti-tumor-activity-of-novel-il-2-therapeutic-au-007/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/aulos-bioscience-presents-preclinical-data-demonstrating-anti-tumor-activity-of-au-007-a-novel-il-2-therapeutic-at-36th-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/aulos-bioscience-to-present-new-preclinical-data-on-computationally-evolved-il-2-human-antibody-au-007-at-36th-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/jim-vasselli-m-d-joins-aulos-bioscience-as-chief-medical-officer/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/aulos-bioscience-appoints-leo-redmond-as-chief-financial-officer/ 2021-10-20T15:46:14+00:00 0.80 https://aulosbio.com/mace-rothenberg-m-d-joins-aulos-bioscience-board-of-directors/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/aulos-bioscience-appoints-aron-knickerbocker-as-ceo/ 2022-01-07T12:54:58+00:00 0.80 https://aulosbio.com/atp-and-biolojic-design-launch-aulos-bioscience-to-develop-highly-differentiated-il-2-antibody-approach-to-fighting-cancer/ 2021-10-20T15:46:14+00:00 0.80